newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Preeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person